Domvanalimab (dom) is an Fc-silent investigational monoclonal antibody. AB308 is an Fc-enabled investigational anti-TIGIT monoclonal antibody. Both bind to TIGIT and may enable CD155:CD226 interaction and subsequent immune cell activation.
Etrumadenant (etruma) is an investigational small molecule, dual A2A/A2B adenosine receptor antagonist. Quemliclustat (quemli) is an investigational small molecule CD73 inhibitor. AB598 is an investigational anti-CD39 antibody. Adenosine is an immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.
Zimberelimab (zim) is an investigational monoclonal antibody that binds PD-1 and may restore the antitumor activity of T cells.
AB521 is an investigational small-molecule inhibitor of the hypoxic transcriptional regulator HIF-2a that has demonstrated potent antitumor activity in xenograft models of cancer.